Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 10, 2022 08:00 ET
|
Phathom Pharmaceuticals
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H....
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 04, 2022 08:01 ET
|
Phathom Pharmaceuticals
Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE)Provides capital for launch of vonoprazan in H. pylori...
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 01, 2022 08:01 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Global Digital therapeutics Market to Perceive Noteworthy Growth Due to Growing Cases of Chronic Disorders Worldwide [175-Pages] | Divulge by Research Dive
March 21, 2022 09:03 ET
|
Research Dive
New York, USA, March 21, 2022 (GLOBE NEWSWIRE) -- A new report on the global digital therapeutics market has been added by Research Dive to its repository. As per the report, the market is expected...
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 14, 2022 08:02 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
March 01, 2022 16:04 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
February 09, 2022 16:04 ET
|
Phathom Pharmaceuticals
Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo...
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
November 08, 2021 08:00 ET
|
Phathom Pharmaceuticals
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May...
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
October 21, 2021 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
October 18, 2021 07:00 ET
|
Phathom Pharmaceuticals
Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phasesVonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus...